Lordelo (PT)
{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~95 mi. (Vigo, Spain, +383 more cities)
facility
Complexo Hospitalario de Vigo. Hospital Álvaro Cunqueiro; Servicio de Oncología
biomarker
ER Negative, +2 more biomarkers
condition
Breast Carcinoma
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
city
~95 mi. (Vigo, Spain, +260 more cities)
facility
Hospital Alvaro Cunqueiro; Servicio de Oncologia
biomarker
ERBB2 Amplification, +1 more biomarker
condition
Invasive Breast Carcinoma
drug
ado-trastuzumab emtansine, +1 more drug
drug type
immunotherapy, +1 more type
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~95 mi. (Vigo, Spain, +115 more cities)
facility
Complexo Hospitalario de Vigo. Hospital Álvaro Cunqueiro; Servicio de Oncología
biomarker
ERBB2 Amplification, +7 more biomarkers
condition
Breast Carcinoma
drug
ado-trastuzumab emtansine, +1 more drug
drug type
immunotherapy, +1 more type